Monitor Phase 1 data for MT-001 expected mid-2027 and regulatory filing for MT-002 in Q1 2027. The $490M financing provides a multi-year runway, reducing near-term dilution risk.
Drugs in focus
INM drug pipeline →MT-001
● Neutral Named in this 8-K- Impact
- Phase
- Preclinical (IND-enabling)
- Time to market
- Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
- Next catalyst
- None dated
What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $16.00entry
- T+1 · 7d ago −23.75%α −23.38% · $12.20
- T+5 · 20h ago +16.25%α +17.94% · $18.60
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mentari Therapeutics (formerly InMed Pharmaceuticals) completed its merger with Mentari Therapeutics and closed $490M in private financings. The combined company trades under MTRI and has a clinical pipeline targeting migraine prevention with two lead candidates, MT-001 and MT-002.
Key Facts
- Merger between InMed Pharmaceuticals and Mentari Therapeutics closed on November 9, 2026
- Combined company renamed Mentari Therapeutics, Inc., trading under ticker MTRI on Nasdaq
- Private placement financings closed with gross proceeds of approximately $490 million
- Proceeds include conversion of $50.0 million of previously issued convertible notes plus accrued interest
- Approximately 58.3 million shares of common stock and common stock equivalents outstanding post-transaction
- MT-001 (anti-PACAP monoclonal antibody) in Phase 1 clinical trial with initial data expected mid-2027
- MT-002 (bispecific anti-PACAP/anti-CGRP antibody) on track for regulatory filing Q1 2027 with data expected year-end 2027
- Todd Shegog appointed to Board of Directors as Chair of Audit Committee
Financial Impact
Combined company raised $490M in gross proceeds from private placements, providing cash runway into 2029. Post-merger share count approximately 58.3 million shares and equivalents.
Risk Factors
- Clinical-stage company with no approved products; MT-001 and MT-002 are investigational
- Phase 1 data for MT-001 not expected until mid-2027; no near-term revenue catalysts
- Significant dilution from the reverse stock split and private placement financings
- Competition from existing anti-CGRP therapies for migraine
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-452706 |
| Document: d183007dex991.htm | 0001193125-26-452706 |
| Document: 0001193125-26-452706-index-headers.html | 0001193125-26-452706 |
| Document: 0001193125-26-452706-index.html | 0001193125-26-452706 |
| Document: 0001193125-26-452706.txt | 0001193125-26-452706 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers